Primary Ovarian Insufficiency Market Report 2026

Primary Ovarian Insufficiency Market Overview

• Primary Ovarian Insufficiency market size has reached to $1.18 billion in 2025 • Expected to grow to $1.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: The Increasing Prevalence Of Autoimmune Disorders Driving The Growth Of The Primary Ovarian Insufficiency Market Due To Higher Susceptibility To Immune Dysregulation • North America was the largest region in 2025.

What Is Covered Under Primary Ovarian Insufficiency Market?

Primary ovarian insufficiency (POI) is a condition where the ovaries stop functioning normally before the age of 40, leading to reduced estrogen production and irregular or absent menstrual periods. It can result in infertility and is often associated with hormonal imbalances despite the presence of some ovarian activity. The main types of primary ovarian insufficiency are hormone replacement therapy (HRT), calcium and vitamin D supplements, in vitro fertilization (IVF), stem cell therapy, and other types. Hormone replacement therapy (HRT) refers to the medical treatment in which hormones, typically estrogen and progesterone, are supplemented to alleviate symptoms caused by hormonal imbalances or deficiencies, especially during menopause. The various diagnostic methods include blood tests, ultrasound imaging, and genetic testing. This condition can affect individuals across different age groups, including those under 20, 20 to 30 years old, 30 to 45 years old, and those over 45. These are used for various end users such as hospitals, clinics, and specialty fertility centers.

What Is The Primary Ovarian Insufficiency Market Growth Forecast?

The primary ovarian insufficiency market size is expected to see strong growth in the next few years. It will grow to $1.88 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing investment in regenerative medicine research, rising demand for early diagnosis solutions, expansion of precision medicine approaches, growing focus on non-invasive fertility treatments, increasing availability of advanced reproductive technologies. Major trends in the forecast period include increasing adoption of personalized hormone therapies, rising use of advanced diagnostic testing, growing focus on fertility preservation solutions, expansion of regenerative and stem cell-based treatments, enhanced integration of multidisciplinary care models.

Global Primary Ovarian Insufficiency Market Segmentation

1) By Type: Hormone Replacement Therapy (HRT), Calcium and Vitamin D Supplements, In Vitro Fertilization (IVF), Stem Cell Therapy, Other Types 2) By Diagnosis Method: Blood Tests, Ultrasound Imaging, Genetic Testing 3) By Application: Less Than 20 Years Old, 20 To 30 Years Old, 30 To 45 Years Old, Perimenopausal Age Group Exclusion As POI Occurs Before 40 4) By End-Users: Hospitals And Clinics, Specialty Fertility Centers Subsegments: 1) By Hormone Replacement Therapy: Estrogen Therapy, Estrogen-Progestin Therapy, Transdermal Patches, Vaginal Estrogen Products, Oral Hormone Therapy 2) By Calcium And Vitamin D Supplements: Calcium Carbonate, Calcium Citrate, Vitamin D2 (Ergocalciferol), Vitamin D3 (Cholecalciferol), Combined Calcium + Vitamin D Formulations 3) By In Vitro Fertilization: Conventional In Vitro Fertilization, Intracytoplasmic Sperm Injection (ICSI), Egg Donation In Vitro Fertilization, Embryo Freezing And Transfer, Preimplantation Genetic Testing (PGT) 4) By Stem Cell Therapy: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy, Mesenchymal Stem Cell (MSC) Therapy, Ovarian Stem Cell Transplantation 5) By Other Types: Psychological Counseling And Support Therapies, Assisted Reproductive Technologies (other than IVF), Immunomodulatory Therapies, Lifestyle And Dietary Interventions

What Are The Drivers Of The Primary Ovarian Insufficiency Market?

The increasing prevalence of autoimmune disorders is expected to propel the growth of the primary ovarian insufficiency market going forward. Autoimmune disorders refer to a group of diseases where the immune system mistakenly attacks and damages the body's own healthy cells and tissues. The increasing prevalence of autoimmune disorders is primarily due to genetic predisposition, where individuals inherit specific genes that make them more susceptible to immune system malfunctions. Primary ovarian insufficiency (POI) can help in understanding autoimmune disorders by revealing how hormonal imbalances and immune system dysregulation interact, leading to a heightened risk of autoimmune diseases in affected individuals. For instance, in 2025, according to the WeCovr is an UK-based embedded insurance platform, It's estimated that over 3.5 million people in the UK will be living with an autoimmune disease by the end of 2025, a figure that has risen by nearly 40% since the early 2000s This is higher than earlier estimates of 3% to 9%. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the primary ovarian insufficiency industry. The rising emphasis on preventive care is expected to propel the growth of the primary ovarian insufficiency market going forward. Preventive care encompasses healthcare services and interventions aimed at preventing disease, detecting health conditions early, and promoting overall health and well-being. Preventive care is rising due to increasing awareness of early disease detection, which helps reduce severe health complications and lowers long-term healthcare costs. Primary ovarian insufficiency (POI) contributes to the rising emphasis on preventive care by highlighting the need for early screening, timely interventions, and fertility preservation to reduce long-term health risks in affected women. For instance, in March 2024, according to a report by the Government of the United Kingdom, a UK-based information website, in March 2023, the percentage of people with type 1 diabetes in England receiving 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% the previous year. Therefore, the rising emphasis on preventive care is driving the growth of the primary ovarian insufficiency industry.

Key Players In The Global Primary Ovarian Insufficiency Market

Major companies operating in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals AS, PreventionGenetics LLC, The Fertility Partnership UK, Celmatix Inc, IVIRMA Global, Bioscience Institute SpA, Sparsh Diagnostics Pvt Ltd, Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty Ltd, OvaScience Inc, Merck KGaA, Roche Holding AG, Pfizer Inc, Novartis AG, AbbVie Inc, Eli Lilly And Company, Bayer AG, Takeda Pharmaceutical Company Limited

What Are Latest Mergers And Acquisitions In The Primary Ovarian Insufficiency Market?

In July 2023, EQT Private Capital Asia, a China-based investment company, acquired a 60% stake in Indira IVF Hospital Pvt. Ltd. for $1.1 billion. With this acquisition, EQT Private Capital Asia aims to expand Indira IVF’s market leadership across India and Asia, enhance its technological capabilities, and scale operations to capitalize on the rapidly growing fertility services market. Indira IVF Hospital Pvt. Ltd. is an India-based fertility clinic that provides specialized diagnosis and treatment for primary ovarian insufficiency (POI), also known as premature ovarian failure (POF).

Regional Outlook

North America was the largest region in the primary ovarian insufficiency market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Primary Ovarian Insufficiency Market?

The primary ovarian insufficiency market consists of revenues earned by entities by providing services such as fertility treatments, diagnostic and genetic testing services, osteoporosis management services, and endocrinology consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ovarian insufficiency market also consists of sales of products including genetic testing kits, bone health supplements, psychological and supportive care products, testosterone therapy, and antioxidant supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Primary Ovarian Insufficiency Market Report 2026?

The primary ovarian insufficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the primary ovarian insufficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.